+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial



Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial



Journal of the American College of Cardiology 64(2): 158-168



Patients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional aortic valve replacement (AVR) in the PARTNER (Placement of Aortic Transcatheter Valves) trial were randomized to transcatheter aortic valve replacement (TAVR) versus AVR (PARTNER-A arm) or standard therapy (PARTNER-B arm). This study compared when and how deaths occurred after TAVR versus surgical AVR or standard therapy. The PARTNER-A arm included 244 transfemoral (TF) and 104 transapical (TA) TAVR patients, and 351 AVR patients; the PARTNER-B arm included 179 TF-TAVR patients and 179 standard therapy patients. Deaths were categorized as cardiovascular, noncardiovascular, or uncategorizable, and were characterized by multiphase hazard modelling. In the PARTNER-A arm, the risk of death peaked after randomization in the TA-TAVR and AVR groups, falling to low levels commensurate with the U.S. population within 3 months. Early risk was less in TF-TAVR patients, resulting in initial superior survival; between 12 and 18 months, risk increased, such that within 2 years, TF-TAVR and AVR patients had similar survival rates. Cardiovascular, noncardiovascular, and uncategorizable deaths for TF-TAVR were 37%, 43%, and 20%, respectively, versus 22%, 41%, and 37%, respectively, for TA-TAVR and 33%, 43%, and 24%, respectively, for AVR. In the PARTNER-B arm, risk with standard therapy was 60% per year; TF-TAVR reduced risk to 20% per year, resulting in 0.5 years of life added within 2.5 years. In inoperable AS patients, TAVR substantially reduced the risk of cardiovascular death. In high-risk patients, TA-TAVR and AVR were associated with elevated peri-procedural risk more than with TF-TAVR, although cardiovascular death was higher after TF-TAVR. Therefore, TF-TAVR should be considered the standard of care for severely symptomatic inoperable patients or those at high risk of noncardiovascular mortality after conventional surgery. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269835

Download citation: RISBibTeXText

PMID: 25011720

DOI: 10.1016/j.jacc.2013.08.1666


Related references

TCT-106 Atrial Fibrillation is Associated with Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR: Insights From the PARTNER 2A and PARTNER 2 S3i Trials. Journal of the American College of Cardiology 70(18): B46-B47, 2017

TAVR in Intermediate-Risk Patients: A Review of the PARTNER 2 Trial and its Future Implications. Journal of Heart Valve Disease 25(6): 653-656, 2016

Analysis of cardiovascular mortality, bleeding, vascular and cerebrovascular events in patients with atrial fibrillation vs. sinus rhythm undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVR). Bmc Cardiovascular Disorders 17(1): 298, 2017

TCT-754 Clinical and Left Ventricular Functional Outcomes Associated with Cardiac Biomarker Elevation after Transapical TAVR: A Sub-analysis from the PARTNER Trial. Journal of the American College of Cardiology 62(18): B229-B230, 2013

Influence of sex on mortality and perioperative outcomes in patients undergoing TAVR: insights from the FRANCE 2 registry. Journal of the American College of Cardiology 65(7): 755-757, 2015

Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. Journal of Cardiovascular Computed Tomography 12(4): 338-343, 2018

TAVR in Low-Risk Patients: 1-Year Results From the LRT Trial. Jacc. Cardiovascular Interventions 12(10): 901-907, 2019

Safety and feasibility of PCI in patients undergoing TAVR: A systematic review and meta-analysis. Heart and Lung 46(2): 92-99, 2017

3-Year Results of a TAVR Trial in High Surgical Risk Patients. Journal of the American College of Cardiology 67(22): 2575-2577, 2016

Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial. Jacc. Cardiovascular Imaging, 2016

Does the Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment (CGA), predict mortality in cancer patients? Results of a prospective observational trial. Journal of Geriatric Oncology 4(3): 208-217, 2013

TCT-686 Impact of Left Ventricular Remodeling on Clinical Outcomes after TAVR: Insights from the PARTNER I Trial. Journal of the American College of Cardiology 64(11): B200-B201, 2014

Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. Journal of the American College of Cardiology 64(2): 129-140, 2014

Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial. Circulation. Cardiovascular Interventions 9(1): E002766, 2016

TCT-794 Derivation of TAVR Combined Mortality and Morbidity Risk Score for Predicting 1 year Mortality and Morbidity After TAVR. Journal of the American College of Cardiology 70(18): B270-B271, 2017